epsteinbarr
viru
ebv
ubiquit
viru
preval
human
popul
transmit
infect
saliva
ebv
caus
agent
infecti
mononucleosi
im
implic
malign
lymphoid
epitheli
origin
past
decad
research
effort
primarili
focus
dissect
mechan
ebvinduc
oncogenesi
present
altern
facet
oncoviru
ebv
applic
research
therapi
final
discuss
prospect
util
ebv
nasopharyng
carcinoma
npc
diagnosi
therapi
also
present
epsteinbarr
viru
ebv
first
human
tumor
viru
discov
year
ago
base
electron
microscopi
observ
viru
particl
burkitt
lymphoma
bl
biopsi
belong
human
herpesviru
famili
infect
world
popul
ebv
exhibit
dual
tropism
infect
b
lymphocyt
epitheli
cell
infect
viru
childhood
usual
asymptomat
ebv
infect
adolesc
manifest
infecti
mononucleosi
im
immunocompet
individu
replic
ebvinfect
b
cell
kept
check
cell
immun
drive
viru
dormanc
nonetheless
viru
capabl
persist
human
popul
restrict
express
viral
product
ebvencod
small
rna
eber
viral
microrna
mirna
establish
latenc
profil
memori
b
cell
pool
opportunist
human
pathogen
ebv
propos
involv
b
cell
malign
observ
posttranspl
lymphoma
aidsrel
lymphoma
delic
balanc
host
immun
ebvinfect
b
cell
perturb
unlik
ebvassoci
lymphoid
malign
link
ebv
epitheli
malign
less
clear
although
viru
transform
immort
b
cell
upon
infect
viru
readili
infect
epitheli
cell
put
forth
contribut
host
genet
environment
factor
ebvassoci
npc
therefor
believ
ebv
establish
latenc
aberrantli
epitheli
cell
alreadi
undergon
premalign
genet
chang
essenti
initi
step
develop
npc
articl
discuss
util
target
ebv
gene
product
viral
episom
whole
viru
research
screen
diagnost
futur
treatment
npc
fig
ebv
gene
productzebra
ebv
zebra
protein
product
gene
basic
leucin
zipper
transcript
activ
requir
latent
lytic
reactiv
apart
intrins
function
activ
ebv
lytic
cycl
zebra
shown
recent
cross
cell
membran
accumul
nucleu
lymphocyt
specif
minim
domain
consist
amino
acid
peptid
within
zebra
protein
found
effici
deliv
high
molecular
weight
protein
across
lipid
bilay
cell
membran
via
direct
nonendocytosisdepend
transloc
demonstr
marchion
et
al
util
permit
higheffici
deliveri
fulli
biolog
activ
cargo
protein
within
two
hour
almost
toxic
inde
use
apoptosi
melanoma
colorect
tumor
cell
observ
upon
success
deliveri
f
subunit
eukaryot
initi
factor
across
cell
membran
taken
togeth
ebv
peptidebas
deliveri
system
present
could
repres
potenti
power
tool
cancer
treatment
facilit
deliveri
coupl
therapeut
cancer
cell
ebv
episom
vector
first
describ
yate
et
al
compris
latent
origin
plasmid
replic
orip
transactiv
protein
ebv
nuclear
structur
orip
consist
famili
repeat
fr
element
dyad
symmetri
ds
element
contain
multipl
consensu
sequenc
bind
ds
serv
site
initi
replic
fr
function
anchor
point
bind
ensur
equal
partit
viral
episom
daughter
cell
result
episom
vector
replic
per
cell
cycl
synchroni
host
chromosom
extrachromosom
entiti
given
nonintegr
characterist
ebv
episom
abil
accommod
larg
transgen
insert
use
ebv
episom
vector
extend
genet
studi
protein
product
gene
therapi
ipsc
gener
prior
establish
nextgener
sequenc
studi
human
genom
technic
challeng
human
genom
inher
larg
overcom
problem
ebv
episom
util
shuttl
vector
hous
larg
fragment
human
genom
sequenc
size
rang
kb
high
insert
capac
ebv
episom
allow
deliveri
intact
genom
dna
loci
achiev
physiolog
level
transgen
express
construct
known
human
artifici
episom
chromosom
permit
preserv
human
sequenc
delet
recombin
rearrang
facilit
transfer
recoveri
express
system
differ
organ
use
ebv
episom
greatli
expedit
process
physic
map
function
identif
human
gene
product
recombin
protein
stabl
cell
line
capabl
chromosom
express
transgen
ideal
rare
use
viral
vector
retroviru
adenoviru
baculoviru
ensur
stabl
express
virus
modifi
prevent
uncontrol
replic
case
accident
releas
apart
labori
technic
challeng
gener
recombin
virus
random
integr
transgen
host
chromosom
use
recombin
virus
confound
transgen
express
impact
recombin
protein
product
regard
use
ebv
episom
circumv
errat
transgen
express
recombin
protein
product
result
random
integr
episom
vector
persist
multipl
copi
per
cell
result
amplif
transgen
higher
protein
express
rel
short
period
time
inde
rapid
high
transgen
express
achiev
use
ebv
episom
absenc
drug
select
coher
excel
capac
accommod
larg
transgen
express
kb
human
bglobe
transgen
report
stabl
sustain
express
month
even
though
high
transgen
express
also
achiev
use
plasmidbas
vector
constitut
promot
cmv
promot
sustain
plasmid
alway
concern
plasmid
often
get
dilut
upon
cell
divis
leverag
bind
interact
protein
ebv
episom
improv
achiev
fast
high
yield
recombin
protein
attempt
enhanc
transgen
express
ebv
episom
vector
probabl
attribut
bind
orip
activ
transcript
transgen
orip
enabl
nuclear
import
transgen
establish
mammalian
cell
line
parent
cell
stabli
express
episom
express
transgen
result
threefold
increas
protein
yield
report
backliw
et
al
util
combin
higheffici
polyethyleneiminebas
transfect
result
remark
effici
exceed
gl
recombin
protein
notebl
product
recombin
protein
scale
l
adapt
suspens
cultur
report
philipp
et
al
appeal
industri
product
biotechnolog
gene
therapi
therapeut
approach
complement
defici
correct
defect
gene
via
introduct
correct
cdna
dna
system
current
avail
util
viral
vector
deriv
retrovirus
lentivirus
adenovirus
pose
safeti
concern
due
random
insert
accompani
cytopath
effect
therefor
possibl
activ
oncogen
disregard
one
apprehens
incid
gene
therapi
use
retroviru
correct
sever
combin
immun
defici
led
develop
leukemialik
condit
nonintegr
properti
ebv
episom
vector
provid
safer
altern
use
viral
vector
inde
util
ebv
episom
extend
treatment
malign
congenit
disord
accentu
potenti
clinic
applic
howev
effici
gene
deliveri
remain
problem
transfect
procedur
ebv
episom
vector
usual
includ
electropor
intramuscular
inject
transfect
effici
improv
use
combin
cation
liposom
polyamidodamin
pamam
dendrim
anoth
approach
tackl
issu
develop
hybrid
vector
retrovir
adenovir
herp
viral
element
util
deliv
ebvbas
replicon
owe
high
robust
infect
regen
medicin
branch
appli
research
involv
replac
defect
cell
tissu
organ
reinstat
function
advent
induc
ipsc
technolog
embryon
stemlik
cell
directli
reprogram
somat
cell
forc
express
four
transcript
factor
cmyc
earli
day
ipsc
research
yamanaka
factor
effici
deliv
engin
retrovirus
lentivirus
akin
drawback
seen
use
viral
vector
gene
therapi
random
viral
integr
warrant
safeti
consider
make
virallyderiv
ipsc
unsaf
clinic
applic
use
integrationfre
ebv
episom
ipsc
reprogram
prefer
gain
popular
actual
ipsc
use
first
histor
human
trial
macular
degener
reprogram
use
nonintegr
ebv
episom
vector
oncogen
potenti
ebv
best
illustr
abil
infect
b
cell
vitro
transform
b
lymphoblastoid
cell
line
blcl
capabl
indefinit
prolifer
given
abil
ebv
immort
b
cell
becam
appar
gener
b
cell
line
would
preserv
genet
inform
individu
blcl
cultur
continu
provid
unlimit
sourc
biolog
materi
genet
epidemiolog
pedigre
studi
addit
cell
thaw
frozen
user
conveni
enabl
experiment
observ
made
reliabl
time
minim
intrasampl
variabl
apart
use
ebv
episom
ipsc
gener
mention
earlier
aspect
ebv
involv
ipsc
gener
use
ebvblcl
start
cell
type
report
rajesh
et
al
ipsc
success
reprogram
blcl
addit
episom
vector
contain
nanog
intriguingli
mere
ml
peripher
blood
blcl
gener
reprogram
ipsc
capabl
differenti
hematopoiet
neural
cardiac
hepatocytelik
lineag
importantli
ebv
gene
detect
transcript
protein
level
result
blclipsc
passag
use
methodolog
virusfre
ipsc
obtain
make
appeal
futur
clinic
applic
inher
plastic
b
cell
recept
plasmid
eas
gener
blcl
avail
bank
blcl
collect
make
ebvblcl
ideal
sourc
somat
cell
ipsc
gener
posttranspl
lymphoprolif
disord
ptld
condit
wherebi
immunosuppress
graft
recipi
result
inabl
cell
control
prolifer
ebvinfect
b
cell
blcl
express
latenc
iii
profil
vitro
counterpart
ebvinfect
b
cell
ptld
patient
specif
ebvblcl
inject
immunodefici
mice
simul
ptld
patient
b
cell
lymphoprolifer
mous
xenograft
classic
use
model
assess
potenti
therapeut
util
ebvblcl
treatment
ebvassoci
malign
entail
use
stimul
ebvspecif
cytotox
lymphocyt
ctl
treatment
modal
allogen
ebvspecif
ctl
harvest
donor
incub
irradi
blcl
vitro
stimul
expans
ebvspecif
ctl
ebvspecif
ctl
cultur
expand
vitro
prior
administr
ptld
npc
patient
form
adopt
cell
transfer
therapi
advent
use
adopt
ebvspecif
ctl
therapi
treat
ptld
blcl
also
use
stimul
prolifer
ebvspecif
ctl
prior
inject
patient
taken
togeth
use
blcl
relev
model
treatment
ptld
antibodi
second
largest
class
drug
follow
vaccin
use
ebvblcl
also
extend
sphere
antibodi
discoveri
engin
therapeut
antibodi
enter
clinic
trial
mostli
either
phage
display
human
mice
risk
immunogen
therefor
ideal
monoclon
antibodi
mab
clinic
applic
natur
antibodi
produc
human
bodi
result
vivo
immun
respons
regard
fulli
humanderiv
antibodi
obtain
screen
individu
respond
natur
expos
make
specif
humor
respons
diseas
subsequ
select
antigenspecif
b
cell
follow
immort
ebv
use
approach
mani
fulli
human
mab
isol
thu
far
target
dengu
viru
sar
coronaviru
influenza
hcmv
plasmodia
innov
fulli
human
antibodi
platform
involv
screen
individu
natur
expos
endem
region
antigenspecif
reactiv
target
select
antigenspecif
b
cell
eg
flow
cytometr
sort
follow
subsequ
ebv
transform
rescu
antibodi
v
region
sequenc
recombin
protein
product
cho
cell
plant
cell
key
technolog
involv
take
advantag
ebv
transform
abil
immort
immun
antibodysecret
human
blymphocyt
poor
ebv
infect
clone
effici
use
bottleneck
improv
combin
cpg
activ
tolllik
irradi
allogen
mononuclear
cell
feeder
cell
histopatholog
examin
nasopharyng
biopsi
fine
needl
aspir
fnac
neck
lump
gold
standard
npc
diagnosi
detect
ebv
dna
pcr
rna
eberish
help
histopatholog
examin
fail
clinic
doubt
case
occult
primari
submucos
diseas
fnac
due
low
accuraci
radiotherapi
prove
effect
modal
treatment
diseas
diagnos
earli
stage
surviv
probabl
unfortun
patient
npc
alreadi
develop
local
region
spread
upon
diagnosi
therefor
screen
earli
diseas
asymptomat
individu
potenti
may
improv
npc
treatment
outcom
endem
region
presenc
ebv
highli
suggest
npc
sinc
high
associ
ebv
infect
antibodi
specif
ebv
capsid
antigen
igavca
earli
antigen
igaea
plasma
dna
extens
studi
screen
npc
data
endem
nonendem
region
demonstr
plasma
dna
use
screen
diagnosi
stage
followup
prognost
chan
wong
recent
studi
healthi
volunt
demonstr
plasma
ebv
dna
analysi
use
earli
detect
npc
clinic
evid
shao
et
al
prove
plasma
ebv
dna
detect
sensit
specif
marker
serum
igavca
titer
diagnosi
monitor
patient
npc
besid
plasma
antibodi
dna
circul
ebv
shown
serv
potenti
new
serolog
biomark
diagnosi
predict
treatment
efficaci
npc
recent
studi
zheng
et
al
demonstr
ebvencod
detect
via
less
invas
nasopharyng
brush
sampl
diagnos
earlystag
npc
sensit
specif
howev
mirna
detect
need
larg
patient
cohort
across
multipl
center
confirm
success
strategi
target
tumor
cell
depend
clear
differ
tumor
cell
normal
cell
consist
presenc
ebv
everi
cell
undifferenti
npc
provid
uniqu
opportun
target
viru
endem
region
ebv
exclus
found
npc
tumor
cell
normal
cell
ebvtarget
therapi
immunotherapi
recent
review
detail
mani
research
mainli
includ
inhibit
ebv
transform
protein
use
antisens
rna
small
interf
rna
sirna
ribozym
induc
loss
ebv
episom
eg
use
hydroxyurea
trigger
lytic
form
ebv
replic
tumor
cell
express
ie
protein
zta
rta
use
radiat
chemo
drug
demethyl
histon
acetyl
agent
gemcitabin
hdac
inhibitor
phorbol
ester
sodium
butyr
ebv
lytic
replic
promot
viral
antigen
exposur
provok
strong
host
immun
respons
use
conjunct
antivir
prodrug
ganciclovir
enhanc
kill
viru
tumor
cell
adopt
cell
immun
therapi
infus
ex
vivo
expand
autolog
ebvspecif
ctl
peripher
blood
mononuclear
cell
pbmc
activ
immunotherapi
vaccin
puls
autolog
monocytederiv
dendrit
cell
viral
vector
load
ebv
peptid
ebvtarget
therapi
immunotherapi
repres
novel
therapi
current
becom
center
interest
research
develop
npc
treatment
ebvtarget
therapi
far
clinic
breakthrough
yet
although
cytolyt
viru
activ
clva
therapi
patient
endstag
npc
show
biolog
effect
toler
moder
safeti
current
immunebas
strategi
repres
option
clinic
benefit
treatment
advanc
knowledg
develop
new
therapi
emerg
genomewid
mutat
profil
find
npc
rel
low
level
genom
alter
compar
cancer
theres
find
suggest
epigenet
alter
possibl
oncogen
featur
ebv
infect
neoplasia
henc
target
dysregul
epigenet
regul
might
candid
target
npc
cancer
therapi
recent
prokaryot
type
ii
system
adapt
genet
engin
mammalian
cell
allow
research
edit
genom
unpreced
speed
precis
highli
precis
versatil
system
use
cancer
model
cancer
genom
function
analys
cancer
drug
target
screen
proof
concept
studi
kanda
et
al
found
cleavag
ebv
episom
dna
enabl
clone
diseaseassoci
viral
strain
unpreced
effici
two
gastric
cancer
cellderiv
novel
ebv
strain
clone
technolog
acceler
discoveri
new
ebv
strain
variant
associ
npc
provid
import
clue
mechan
ebvmedi
epitheli
carcinogenesi
studi
bl
patientderiv
cell
clearanc
latent
ebv
genom
use
lead
prolifer
arrest
apoptosi
ebvinfect
cell
observ
cytotox
uninfect
cell
feasibl
edit
ebv
genom
bart
also
demonstr
cultur
npc
cell
line
dormant
viral
genom
latent
infect
provid
therapeut
target
antivir
drug
develop
thu
strategi
may
lead
gener
approach
cure
latent
viral
infect
although
mani
hurdl
remain
approach
could
use
clinic
method
safe
effici
deliveri
rapid
expans
knowledg
field
ebv
biolog
past
decad
research
empow
util
ebv
domain
gene
therapi
regen
medicin
gener
clinicalgrad
ipsc
antibodi
discoveri
grow
evid
ebvinduc
oncogenesi
lymphoid
epitheli
malign
role
ebv
play
mere
associ
inde
emphasi
role
ebv
play
observ
increas
develop
immunotherapeut
ebvtarget
therapeut
particularli
clinic
trial
use
ebvctl
treat
npc
lymphoma
demonstr
promis
result
understand
continu
grow
applic
labelledebv
rnadna
protein
track
cancer
cell
monitor
metastasi
defin
resect
margin
surgic
procedur
envis
